CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has provided updated information on the manufacturing of its lead drug candidate, Berubicin. The company announced it has reached key milestones in the manufacturing process as it has followed a dual-track, … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Progress Report on Critical Steps for Manufacturing of Leading Drug Candidate”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, was featured in an editorial by Financial News Media. The piece, titled “Global Brain Tumor Therapeutics Market Targeted to Reach $3.4 Billion by 2025,” covers CNSP and other biotech … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Featured in Editorial Projecting Significant Growth for Global Brain Tumor Therapeutics Sector”
CNS Pharmaceuticals (NASDAQ: CNSP) (“CNS”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, this morning announced the appointment of Patrick Wen, M.D., an accomplished neuro-oncologist, to the company’s Science Advisory Board. “We are excited to add Dr. Wen, a neuro-oncologist with … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Appoints Dr. Patrick Wen to Science Advisory Board”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently announced its engagement of Worldwide Clinical Trials as the contract research organization (“CRO”) for its upcoming Berubicin clinical trials. Worldwide, which specializes in therapeutic areas where there remain … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Engages Worldwide to Further Drive Berubicin’s Clinical Development”
CNS Pharmaceuticals (NASDAQ: CNSP), a biotechnology company specializing in the development of novel treatments for brain tumors, received positive feedback from the U.S. Food and Drug Administration (“FDA”) for its Pre-IND (Investigational New Drug) meeting proposal to use Berubicin, a lyophilized drug product, in Phase II clinical trials. The FDA indicated, in response to CNS … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces Positive FDA Pre-IND Guidance for Berubicin”
CNS Pharmaceuticals (NASDAQ: CNSP) is a biotechnology company specializing in the development of novel treatments for primary and metastatic brain and central nervous system tumors. Its lead candidate Berubicin is for the treatment of glioblastoma, a type of brain cancer currently considered incurable, as well as pancreatic and ovarian cancers, and lymphomas. The company entered … Continue reading “CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Starts Presentation at 12th Annual LD Micro Main Event”
Related Press Release CNS Pharmaceuticals (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently announced the activation of its first clinical trial sites in Europe for the ongoing potentially pivotal global trial evaluating Berubicin for … Continue reading “NetworkNewsAudio – CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial”
